click enter text
updat model estim increas primarili
pharmedium exit share repo
ep expect driven upsid pharma rel
model increas ep guidanc almost
increas explain pharmedium share repurchas announc
made difficult decis shut pharmedium busi due
on-going regulatori oper issu number go
move given loss remov adjust earn
clearli disappoint outcom rel potenti sell busi
acquir return profit although
compani receiv tax benefit next year
quarter solid absolut term expect increas follow
gener posit tone distributor healthcar
confer estim increas primarili due pharmedium share
repurchas assumpt target price unchang
revis guidanc rais ep guidanc
report show page decis shut
unprofit pharmedium busi drove
improv pre-tax incom impli guidanc compon adjust
pharmedium abc guidanc assumpt share repurchas
ep rais appear attribut core oper factor
note less beat although fair get core
guidanc rais earli posit ebit guid compani
pharma segment increas msd lsd -to-msd
estim chang ep estim
increas vs prior estim note
increas ep come push
assum start date opioid settlement payment calendar
remaind driven pharmedium line item ep bridg
found page
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
exhibit ep bridg ep ep
note calcul base ebit margin exampl show posit contribut mean revenu grow quickli
compani data factset wolf research llc
exhibit ep bridg ep ep
note calcul base ebit margin exampl show posit contribut mean revenu grow quickli
compani data factset wolf research llc
page
exhibit pharmedium contribut improv guidanc
compani materi wolf research
exhibit ep bridg initi guidanc revis
compani materi wolf research
page
net tax pre-tax ebit pre-tax chang changeiniti guidanceiniti ep guidanc oper ep guidanc impact vs prior guidanc
